Taplitumomab paptox
Taplitumomab paptox
Taplitumomab paptox (pronunciation: tap-li-tu-mo-mab pap-tox) is a monoclonal antibody designed for the treatment of cancer. It was developed by GlaxoSmithKline and is also known by its developmental code name, GSK2618960.
Etymology
The name Taplitumomab paptox is derived from the International Nonproprietary Naming (INN) system for pharmaceutical substances. The prefix "Tapli-" is used for monoclonal antibodies targeting tumor cells, "-tumomab" indicates that it is a murine (mouse) monoclonal antibody, and "paptox" signifies that it is conjugated with a bacterial toxin.
Mechanism of Action
Taplitumomab paptox is a monoclonal antibody that targets the CD22 antigen, a protein found on the surface of B cells. The "paptox" part of the drug is a bacterial toxin that is conjugated to the antibody. Once the antibody binds to the CD22 antigen, the toxin is internalized by the cell, leading to cell death.
Clinical Trials
Taplitumomab paptox has been studied in clinical trials for the treatment of Non-Hodgkin lymphoma and other B-cell malignancies. However, as of 2021, it has not been approved for use by any regulatory authority.
Related Terms
External links
- Medical encyclopedia article on Taplitumomab paptox
- Wikipedia's article - Taplitumomab paptox
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski